Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice
Conclusions The poor response of liver cancers to αPD‐L1 therapy is largely attributable to
a unique hepatic immunotolerant microenvironment, independent of tumor origins or types.
The success of a combinatorial immunotherapy relies on coordinated inhibition or activation
of various innate and adaptive immune cell activities.
a unique hepatic immunotolerant microenvironment, independent of tumor origins or types.
The success of a combinatorial immunotherapy relies on coordinated inhibition or activation
of various innate and adaptive immune cell activities.